Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?

It can be exciting to buy a stock that has been red hot and to jump on the bandwagon -- but doing so can come with significant risks. At some point, there's a danger that the stock's rally could dissipate, and at that point, a sell-off may ensue. In other cases, however, there may still be plenty of room for a stock to rise higher, especially if its value still isn't all that expensive.Where Summit Therapeutics (NASDAQ: SMMT) falls on that spectrum is a big question mark right now. It has been among the hottest healthcare stocks to own over the past 12 months, as its valuation has skyrocketed more than 500%. Investors have generated massive returns from the company.But which category does the stock fall into? Is it in danger of hitting a peak soon, or could this still be just the beginning of an even greater rally ahead?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool